{
    "clinical_study": {
        "@rank": "142736", 
        "arm_group": [
            {
                "arm_group_label": "Experimental: AREDS 2 Vitamin formula 1g", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive oral supplementation with the commercially available \"AREDS2\" vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
            }, 
            {
                "arm_group_label": "Eye Omega Advantage 2g", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage\u00ae and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)"
            }
        ], 
        "brief_summary": {
            "textblock": "The effect of omega-3-fatty acids on blood levels omega-3 fatty acids in patients with\n      age-related macular degeneration."
        }, 
        "brief_title": "Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "There is observational data in the current literature suggesting that the intake of foods\n      high in marine sources of omega-3 fatty acids, such as fish, may lower the risk of\n      developing age-related macular degeneration (AMD).  A large prospective study is underway to\n      determine whether oral supplementation with 1 gram of omega-3 fatty acids is beneficial for\n      subjects with dry AMD.  The purpose of our study is to evaluate the change in serum omega-3\n      index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid\n      supplementation versus 2 grams."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study.\n\n          -  Have AREDS category 3 or 4 disease.\n\n          -  Category 3: Many medium sized drusen or one or more large drusen in one  or both eyes\n\n          -  Category 4: Geographic atrophy or choroidal neovascularization in one eye.\n\n        Exclusion Criteria:\n\n          -  Women of child-bearing age with positive urine pregnancy tests or desire to conceive\n             during the course of the study.\n\n          -  Patients with a known fish allergy.\n\n          -  Patients currently taking supplementation with omega-3 fatty acids and have an\n             omega-3 index of greater than 4%."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653184", 
            "org_study_id": "Omega 20120660", 
            "secondary_id": "Protocol #20120660"
        }, 
        "intervention": {
            "arm_group_label": [
                "Experimental: AREDS 2 Vitamin formula 1g", 
                "Eye Omega Advantage 2g"
            ], 
            "description": "The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.", 
            "intervention_name": "Omega-3 fatty acid", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AMD", 
            "Vision loss", 
            "omega-3", 
            "supplement", 
            "age related macular degeneration"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cherry Hill", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08002"
                    }, 
                    "name": "Mid Atlantic Retina- Cherry Hill"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethlehem", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18020"
                    }, 
                    "name": "Mid Atlantic Retina - Bethlehem"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huntingdon Valley", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19006"
                    }, 
                    "name": "Mid Atlantic Retina- Hungtindon Valley"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Mid Atlantic Retina- Wills Eye Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Oral Supplementation With Omega-3 Fatty Acids on Serum Omega-3 Levels in Patients With Age-related Macular Degeneration: A Randomized Controlled Trial.", 
        "overall_official": {
            "affiliation": "Mid Atlantic Retina", 
            "last_name": "Mitchell Fineman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the change in omega-3 index using an omega-3 index serum test, in patients with dry AMD given the commercially available AREDS2 formula supplementation (containing 1gram of omega-3 fatty acids in ethyl ester formulation) compared to patients given a similar vitamin combination with 2 grams of omega-3 fatty acids.", 
            "measure": "Change in omega-3 index", 
            "safety_issue": "No", 
            "time_frame": "Monthly for 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653184"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Wills Eye", 
        "sponsors": {
            "collaborator": {
                "agency": "Physician Recommended Nutriceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Wills Eye", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}